CLR 131 Granted Orphan Drug Status in Europe for Myeloma Treatment
News
CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission for the treatment of multiple myeloma, the ... Read more